SCHEMBL1285404

SCHEMBL1285404

CCOCc1cc2cc(Cl)ccc2oc1=Nc1ccc(Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAOB P27338 5/20 0.36
TSHR P16473 1/20 0.36
MMP2 P08253 1/20 0.34
MMP9 P14780 1/20 0.34
ADAM17 P78536 1/20 0.34
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
LGALS8 O00214 1/20 0.34
LGALS1 P09382 1/20 0.34
LGALS3 P17931 1/20 0.34
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
GPR35 Q9HC97 2/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1285402 1.00 KDM4E (0.39) KDM4ESMN1; SMN2HSD17B10MAOBTSHR
SCHEMBL1284458 0.94 TP53 (0.37) KDM4ESMN1; SMN2HSD17B10MAOBTSHR
SCHEMBL1284459 0.94 TP53 (0.37) KDM4ESMN1; SMN2HSD17B10MAOBTSHR
SCHEMBL1284817 0.93 KDM4E (0.36) KDM4ESMN1; SMN2HSD17B10MAOBTSHR
SCHEMBL1285239 0.93 KDM4E (0.36) KDM4ESMN1; SMN2HSD17B10MAOBTSHR
SCHEMBL1285238 0.93 KDM4E (0.36) KDM4ESMN1; SMN2HSD17B10MAOBTSHR
SCHEMBL1284818 0.93 KDM4E (0.36) KDM4ESMN1; SMN2HSD17B10MAOBTSHR
SCHEMBL1285044 0.93 KDM4E (0.38) KDM4ESMN1; SMN2HSD17B10MAOBTSHR
SCHEMBL1285043 0.93 KDM4E (0.38) KDM4ESMN1; SMN2HSD17B10MAOBTSHR
SCHEMBL1284957 0.92 MAOB (0.45) KDM4ESMN1; SMN2HSD17B10MAOBCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383843-B2 Method for preparing a coumarin compound, chromene compound, and method for preparing a chromene compound KAOHSIUNG MEDICAL UNIVERSITY (TW) 2013-02-26 US disclosed
US-20120088923-A1 METHOD FOR PREPARING A COUMARIN COMPOUND, CHROMENE COMPOUND, AND METHOD FOR PREPARING A CHROMENE COMPOUND KAOHSIUNG MEDICAL UNIVERSITY (TW) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088923-A1 METHOD FOR PREPARING A COUMARIN COMPOUND, CHROMENE COMPOUND, AND METHOD FOR PREPARING A CHROMENE COMPOUND CYP3A7, CYP2A7, F7 KDM4E 3026/4885SMN1; SMN2 4471/4885HSD17B10 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.